|
(Health-NewsWire.Net, May 27, 2015 ) Dallas, TX -- Global Markets Direct’s, ‘Essential Thrombocythemia – Pipeline Review, H1 2015′, provides an overview of the Essential Thrombocythemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.
Complete report on “Essential Thrombocythemia – Pipeline Review, H1 2015” addition with 26 market data tables and 14 figures, spread across 85 pages is available at http://www.rnrmarketresearch.com/essential-thrombocythemia-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2500 for a single user PDF license)
Scope:
• The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=365348 .
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=365348 .
Reasons to Buy:
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
